ARKG Holdings of Regeneron (REGN) - Updated Daily
Join Premium Plan
Key Statistics
Statistics
Clinical Trials (152)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $669.22 |
| ⚖️Weighting | 🧢Market Cap |
| 1.08% | $72.64b |
| 🏋🏿♂️Weight Rank In ARKG | 🧮Price to Sales |
| 34 | 4.52 |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 78 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
| $503.96 | 0.05% |
| Description | |
|---|---|
| Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases. | |
| Website | |
| www.regeneron.com |
Research Notes and Commentary for REGN
August 20, 2021
August 18-20, 2021: ARK Trades and Storylines
Trading Floor
January 13, 2021
Ark Trades and Storylines
Trading Floor